GlassScriptPhysician profile
Lorraine Wentz Bock
NPI 1730164450
$1,518.13
in general payments reported to CMS, 2019-2025
17 companies · $195 in 2025
The $195 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $523 · 2022: $32.87 · 2023: $311 · 2024: $456 · 2025: $195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $940 · Education: $22.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $940.45 |
| Education | $22.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $303.17 | 2023-2025 | |
| Zoll Respicardia, INC. | $151.52 | 2021 | |
| Novo Nordisk INC | $147.87 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Genzyme Corporation | $122.92 | 2021 | |
| Exact Sciences Corporation | $121.29 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $120.44 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $115.34 | 2021 | |
| Boston Scientific Corporation | $113.11 | 2024 | Watchman Access System |
| Lilly USA, LLC | $100.06 | 2024-2025 | Zepbound, Mounjaro |
| Lundbeck LLC | $44.81 | 2024-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $40.43 | 2024 | Rexulti |
| Vanda Pharmaceuticals INC. | $27.64 | 2021-2022 | |
| Heartflow, INC. | $25.64 | 2024 | |
| Abbott Laboratories | $24.00 | 2024 | Freestyle Libre 3 |
| Acella Pharmaceuticals, LLC | $22.00 | 2023 | NP Thyroid 60 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $20.07 | 2024 | Nuzyra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorraine Bock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.